Halleen Jussi M
Institute of Biomedicine, Department of Anatomy, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
Anticancer Res. 2003 Mar-Apr;23(2A):1027-9.
Bone resorbing osteoclasts contain high amounts of tartrate-resistant acid phosphatase (TRACP) 5b and secrete it into the blood circulation. Circulating TRACP 5b activity is derived exclusively from osteoclasts. We have developed a TRACP 5b-specific-immunoassay using a monoclonal antibody O1A that was developed using TRACP 5b purified from human osteoclasts as antigen. Serum TRACP 5b activity has a low diurnal variability, and it does not accumulate in the circulation in renal or hepatic failure. It is elevated in 80% of patients with osteoporosis, while decreased 40-50% after antiresorptive therapy with estrogen and the bisphosphonate alendronate. Preliminary results show that serum TRACP 5b activity is normal in breast cancer patients without bone metastases, and elevated in approximately 80% of breast cancer patients with bone metastases. These results suggest that serum TRACP 5b activity may be a useful marker for the early detection of the spreading of breast cancer cells to bone.
骨吸收破骨细胞含有大量抗酒石酸酸性磷酸酶（TRACP）5b，并将其分泌到血液循环中。循环中的TRACP 5b活性仅来源于破骨细胞。我们利用从人破骨细胞中纯化的TRACP 5b作为抗原制备的单克隆抗体O1A，开发了一种TRACP 5b特异性免疫测定法。血清TRACP 5b活性的昼夜变化较小，在肾衰竭或肝功能衰竭时不会在循环中蓄积。80%的骨质疏松症患者血清TRACP 5b活性升高，而在用雌激素和双膦酸盐阿仑膦酸钠进行抗吸收治疗后降低40 - 50%。初步结果显示，无骨转移的乳腺癌患者血清TRACP 5b活性正常，而约80%有骨转移的乳腺癌患者血清TRACP 5b活性升高。这些结果表明，血清TRACP 5b活性可能是早期检测乳腺癌细胞向骨转移的有用标志物。
